Date of Award
Medical Doctor (MD)
Oscar R. Colegio
This study demonstrates how PDVC57 is an effective pre-clinical model to test immunomodulatory medications for cutaneous SCC in immunocompetent C57Bl/6 mice. We demonstrated the first analysis of myeloid populations within the cutaneous SCC tumor microenvironment and found increased Arg1 expression in TAMs. TAM-inhibition using topically delivered Nor-NOHA effectively decreased tumor size and represents a promising new modality to potentially treat cutaneous SCC. Further clinical trials are warranted to test nor-NOHA in patients with cutaneous SCC and to determine if monotherapy or combination with checkpoint inhibition is more effective.
Mittal, Amit, "Topical Inhibitor Of Arginase Decreases Growth Of Cutaneous Squamous Cell Carcinoma" (2018). Yale Medicine Thesis Digital Library. 3432.